# Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

> **NCT04417530** · PHASE2 · COMPLETED · sponsor: **Aura Biosciences** · enrollment: 22 (actual)

## Conditions studied

- Uveal Melanoma
- Ocular Melanoma
- Choroidal Melanoma

## Interventions

- **DRUG:** AU-011
- **DEVICE:** Suprachoroidal Microinjector
- **DEVICE:** PDT Laser

## Key facts

- **NCT ID:** NCT04417530
- **Lead sponsor:** Aura Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-05
- **Primary completion:** 2024-04-22
- **Final completion:** 2024-04-22
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04417530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04417530, "Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04417530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*